Post Reply
1161-1176 of 1176
is raffles medical worth to accumulate ?
This is an overpriced stock, PE wise.
The yield is also miserable.
It has a stable and growing business though.
It can go down below $1.00.
The yield is also miserable.
It has a stable and growing business though.
It can go down below $1.00.
leongyan ( Date: 15-Dec-2017 14:20) Posted:
|
1.04 looks tempting for short term trade but I am queuing at 1.03.. once bounce up 1.07 sell .. quick trade.. 100 lots make 3k..
leongyan ( Date: 30-Nov-2017 12:54) Posted:
|
No buy back. Every day lau sai...
angmohlin ( Date: 15-Dec-2017 11:22) Posted:
|
1.05 is a resistance level and moving down to 0.99.
Not surprised the institutions are accumulating, if they are.
UOB anticipate start up losses of 14m in 2018 and 9m in 2019 > > One of the institutional holders
DBS downgraded TP to 1.00 > > One of the institutional holders
Happy investing, folks. haha.
UOB anticipate start up losses of 14m in 2018 and 9m in 2019 > > One of the institutional holders
DBS downgraded TP to 1.00 > > One of the institutional holders
Happy investing, folks. haha.
SgTrader17 ( Date: 30-Nov-2017 17:13) Posted:
|
If the start up of two new hospitals with high Capex and they still making money, must be miracle. What is important is that all these factors are already in consideration which pull it's share price down from $1.50. Probably still have people want bottom fishing for the cheapest fishes, but Raffles medical is no ordinary fish. Probably many financial institutions are already accumulating it now. Just a matter of time it finished it's stay in ICU and walk back onto the sunlight. Lol
ozzie75 ( Date: 30-Nov-2017 17:04) Posted:
|
Anticipated start-up losses of 14m in 2018 per UOB Kay Hian.
bishan22 ( Date: 30-Nov-2017 13:31) Posted:
|
Looks like a long stay of 3mths and beyond.... You are right bro....
SgTrader17 ( Date: 30-Nov-2017 13:03) Posted:
|
Checking into ICU means waiting for recovery. Haha. If this stock don't make money by 2018 at this current price, I think SGX really has something not right. At current price with its future expansion plans, it's just a matter of time profits starts rolling in. When all starts to put a hold or sell call on this, it just means trying to encourage people to sell and they can accumulate at the price they wanted to. And then make a big gain in next 2 years. Unless you want to play for just 3 months, then no choice, you should go for other counters. This is a long term treatment and recovery to full running potential by 2019. Just people doesn't like the longer time frame of waiting. But, I think all these wait will be attractively rewarded in the future. Dyodd.
bishan22 ( Date: 30-Nov-2017 10:18) Posted:
|
hope you all took profit at 1.17 level.. clear all and now get wait to reload. RSI looks balanced but wait till it is oversold by next week than enter..low was 1.025 in Sep 2017
Checked in to ICU........................
Nomura Lowers View on Raffles Medical as Patients Switch Facilities -- Market Talk
0234 GMT - Raffles Medical Group will take a hit from a shift in local patients to public facilities and the falling population of highly skilled professionals and foreigners in Singapore, Nomura says. With no signs of a recovery in the medical tourism segment either, Nomura sees limited benefits from the Raffles Hospital extension project. "We remain concerned about weakening growth from local patients near term," says Nomura, which cuts the hospital operator to neutral despite a recent expansion into China that Nomura sees as a long-term positive. The broker also lowers its price target to S$1.25 versus S$1.70 previously. Shares are currently down 1% at S$1.08. ([email protected])
(END) Dow Jones Newswires
November 26, 2017 21:34 ET (02:34 GMT)
0234 GMT - Raffles Medical Group will take a hit from a shift in local patients to public facilities and the falling population of highly skilled professionals and foreigners in Singapore, Nomura says. With no signs of a recovery in the medical tourism segment either, Nomura sees limited benefits from the Raffles Hospital extension project. "We remain concerned about weakening growth from local patients near term," says Nomura, which cuts the hospital operator to neutral despite a recent expansion into China that Nomura sees as a long-term positive. The broker also lowers its price target to S$1.25 versus S$1.70 previously. Shares are currently down 1% at S$1.08. ([email protected])
(END) Dow Jones Newswires
November 26, 2017 21:34 ET (02:34 GMT)
It seem that collection at this price level, very slow. But need " experienced eye" to verify.
Wait for BB to scoop again for 2nd wave... Still no confirmation.. Good luck.
Msport ( Date: 21-Sep-2017 12:41) Posted:
|
https://www.theedgesingapore.com/raffles-medical-group-gets-upgrade-long-term-growth-stays-track
CIMB
Raffles Medical Group
Upgrading ward
■ RFMD&rsquo s share price has corrected c.27% YTD, we now think it looks more attractive
in terms of risk-reward. Upgrade from Reduce to Add with SOP-based TP of S$1.21.
■ At the current price, we believe the Singapore operations have been priced in with
little value ascribed to the long-term potential of its China hospitals.
■ Our best-case scenario for both Singapore and China suggests a S$1.49 TP with 35%
upside, while we think the worst-case scenario is unlikely to materialise.
■ Growing pains for new hospitals in China are inevitable, but a home-field advantage
could help to offset near-term overseas weakness.
Upgrade to Add current level attractive for long-term gain in China
RFMD&rsquo s share price has underperformed 27% YTD we now think it looks attractive to
gain exposure to the growing China healthcare market, especially for long-term investors,
as gestation woes have been largely priced in. RFMD currently trades at 22.5x CY18
EV/EBITDA, below its 5-year historical mean of 23.2x. As we include start-up costs from
the China hospitals, our FY17-19F EPS fall by 1.3-26.2%, resulting in a lower SOP-based
TP of S$1.21. Any near-term share price weakness could be an entry window.
Almost getting the Chongqing hospital for free
We value our Singapore operations at S$1.02/shr, switching to DCF methodology from
19.2x CY18 EV/EBITDA previously. The Chongqing and Shanghai hospitals are valued
at S$0.12/shr and S$0.07/shr, respectively, in our base-case scenario, premised on a 3-
year EBITDA breakeven period. At the current price level, investors are buying a
premium healthcare play in Singapore, with China exposure at a discount. Our S$1.49
TP in a best-case scenario presents even higher upside of 35%.
Home-field advantage to mitigate near-term overseas weakness
Looking beyond the start-up costs in China, we remain positive on the long-term growth
prospects of RFMD&rsquo s Singapore operations, which should benefit from secular trends of
an ageing population and increasing insurance penetration. As the number of
Singaporeans aged 65 and above is expected to double to 900k by 2030, and widening
insurance coverage improves affordability, we expect higher private healthcare demand,
possibly mitigating a soft medical tourism outlook.
Playing the devil&rsquo s advocate
In our worst-case scenario analysis, we derive a value of S$0.77/shr for its Singapore
operations, assuming zero growth rate and deteriorating PBT margins. China hospitals
are worth at least S$0.11/shr, based on a 5-year gestation period (vs. our base case of 3-
year EBITDA breakeven). The combined value of S$0.88/shr implies 20% downside risk
from its current level, which we believe is unlikely.
Worst-case scenario unlikely
We think zero growth for RFMD&rsquo s Singapore business is unlikely. Apart from a steady
base of corporate clients and expanding network of clinics to drive organic growth, we
also expect Holland V&rsquo s full rental contribution from 3Q17F and the hospital extension
(opening in 4Q17F) to provide an earnings uplift in the medium term. A faster-thanexpected
turnaround for both ISOS and Shaw Centre could further boost its bottom-line.
Key risks and catalysts to our Add rating
Further consensus EPS downgrades could pose downside risks to our Add call, while the
successful execution of its first major overseas expansion project in Chongqing could be
the key catalyst for the stock. This note also marks a change in analyst coverage.
CIMB
Raffles Medical Group
Upgrading ward
■ RFMD&rsquo s share price has corrected c.27% YTD, we now think it looks more attractive
in terms of risk-reward. Upgrade from Reduce to Add with SOP-based TP of S$1.21.
■ At the current price, we believe the Singapore operations have been priced in with
little value ascribed to the long-term potential of its China hospitals.
■ Our best-case scenario for both Singapore and China suggests a S$1.49 TP with 35%
upside, while we think the worst-case scenario is unlikely to materialise.
■ Growing pains for new hospitals in China are inevitable, but a home-field advantage
could help to offset near-term overseas weakness.
Upgrade to Add current level attractive for long-term gain in China
RFMD&rsquo s share price has underperformed 27% YTD we now think it looks attractive to
gain exposure to the growing China healthcare market, especially for long-term investors,
as gestation woes have been largely priced in. RFMD currently trades at 22.5x CY18
EV/EBITDA, below its 5-year historical mean of 23.2x. As we include start-up costs from
the China hospitals, our FY17-19F EPS fall by 1.3-26.2%, resulting in a lower SOP-based
TP of S$1.21. Any near-term share price weakness could be an entry window.
Almost getting the Chongqing hospital for free
We value our Singapore operations at S$1.02/shr, switching to DCF methodology from
19.2x CY18 EV/EBITDA previously. The Chongqing and Shanghai hospitals are valued
at S$0.12/shr and S$0.07/shr, respectively, in our base-case scenario, premised on a 3-
year EBITDA breakeven period. At the current price level, investors are buying a
premium healthcare play in Singapore, with China exposure at a discount. Our S$1.49
TP in a best-case scenario presents even higher upside of 35%.
Home-field advantage to mitigate near-term overseas weakness
Looking beyond the start-up costs in China, we remain positive on the long-term growth
prospects of RFMD&rsquo s Singapore operations, which should benefit from secular trends of
an ageing population and increasing insurance penetration. As the number of
Singaporeans aged 65 and above is expected to double to 900k by 2030, and widening
insurance coverage improves affordability, we expect higher private healthcare demand,
possibly mitigating a soft medical tourism outlook.
Playing the devil&rsquo s advocate
In our worst-case scenario analysis, we derive a value of S$0.77/shr for its Singapore
operations, assuming zero growth rate and deteriorating PBT margins. China hospitals
are worth at least S$0.11/shr, based on a 5-year gestation period (vs. our base case of 3-
year EBITDA breakeven). The combined value of S$0.88/shr implies 20% downside risk
from its current level, which we believe is unlikely.
Worst-case scenario unlikely
We think zero growth for RFMD&rsquo s Singapore business is unlikely. Apart from a steady
base of corporate clients and expanding network of clinics to drive organic growth, we
also expect Holland V&rsquo s full rental contribution from 3Q17F and the hospital extension
(opening in 4Q17F) to provide an earnings uplift in the medium term. A faster-thanexpected
turnaround for both ISOS and Shaw Centre could further boost its bottom-line.
Key risks and catalysts to our Add rating
Further consensus EPS downgrades could pose downside risks to our Add call, while the
successful execution of its first major overseas expansion project in Chongqing could be
the key catalyst for the stock. This note also marks a change in analyst coverage.